Related Experiment Video

Updated: Aug 14, 2026

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
13:47

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

2,3 Dimercapto-1-propanol inhibits HIV-1 tat activity, viral production, and infectivity in vitro

S Kubota1, M A el-Farrash, M Maki

  • 1Institute for Virus Research, Kyoto University, Japan.

AIDS Research and Human Retroviruses
|July 1, 1990
PubMed

Insights

The anti-heavy metal drug 2,3 dimercapto-1-propanol (DMP) shows potential against human immunodeficiency virus type 1 (HIV-1). DMP inhibits viral activity and reduces cell susceptibility to HIV-1 infection.

Area of Science:

  • Virology
  • Drug Discovery
  • Immunology

Background:

  • Human immunodeficiency virus type 1 (HIV-1) remains a global health challenge.
  • Current treatments for HIV-1 infection have limitations and side effects.
  • The tat protein is crucial for HIV-1 replication and is a metal-containing transactivating factor.

Purpose of the Study:

  • To investigate the potential of 2,3 dimercapto-1-propanol (DMP), an anti-heavy metal-poisoning drug, as an antiviral agent against HIV-1.
  • To determine the effects of DMP on HIV-1 transactivation, viral production, and cellular susceptibility to infection.

Main Methods:

  • In vitro experiments were conducted to assess DMP's impact on HIV-1.
  • Assays measured the inhibition of transactivation by the tat protein.
  • Viral production levels were quantified after DMP treatment.
  • Cellular sensitivity to HIV-1 infection was evaluated following DMP treatment and pre-treatment.

Main Results:

  • DMP significantly inhibited transactivation mediated by the HIV-1 tat protein.
  • DMP interfered with the production of infectious HIV-1 particles.
  • Pre-treatment and treatment of cells with DMP markedly reduced their susceptibility to HIV-1 infection via unidentified mechanisms.

Conclusions:

  • 2,3 dimercapto-1-propanol (DMP) exhibits pleiotropic effects against HIV-1 in vitro.
  • DMP demonstrates potential as a novel therapeutic agent for AIDS treatment.
  • Further research into DMP's mechanisms could lead to new drug design strategies against HIV-1.

More Related Videos

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion07:22

A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion

Published on: August 14, 2018

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...